Isavuconazole Treatment of Spinal Cord Invasive Aspergillosis Guided by Cerebrospinal Fluid (1,3)-β-d-Glucan Levels in a Patient with Low Interferon-Gamma and Ulcerative Colitis.
Authors
Reidy, PaulO'Toole, Aoibhlinn
Caird, John
McNally, Cora
McConkey, Samuel
de Barra, Eoghan
O’Regan, Siobhán

O'Kelly, Brendan

Issue Date
2022-05-25Keywords
(1,3)-β-d-glucanCNS aspergillosis
fungal CNS infection
Invasive aspergillosis
isavuconazole
Metadata
Show full item recordJournal
Journal of fungi (Basel, Switzerland)DOI
10.3390/jof8060557PubMed ID
35736040PubMed Central ID
PMC9224947Abstract
This case highlights the use of (1,3)-beta-d glucan to direct treatment of a cervical spinal cord Aspergillus fumigatus infection in a 22-year-old woman immunocompromised due to steroid and anti-TNF therapy in the context of ulcerative colitis and interferon gamma deficiency. A 4-year treatment course requiring neurosurgical intervention on four occasions and prolonged antifungal therapy, including isavuconazole, resulted in clinical cure with a corresponding decrease in CSF beta-d-glucan to <30 pg/mL. Serum and CSF galactomannan levels were not elevated at any point during the clinical course.Item Type
ArticleLanguage
enEISSN
2309-608Xae974a485f413a2113503eed53cd6c53
10.3390/jof8060557